Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
2.020
+0.040 (2.02%)
At close: Nov 22, 2024, 4:00 PM
2.000
-0.020 (-0.99%)
After-hours: Nov 22, 2024, 7:10 PM EST
Caribou Biosciences Employees
Caribou Biosciences had 158 employees as of December 31, 2023. The number of employees increased by 21 or 15.33% compared to the previous year.
Employees
158
Change (1Y)
21
Growth (1Y)
15.33%
Revenue / Employee
$72,627
Profits / Employee
-$937,468
Market Cap
182.92M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 158 | 21 | 15.33% |
Dec 31, 2022 | 137 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Nutex Health | 800 |
2seventy bio | 274 |
Cellectis | 221 |
Biodesix | 217 |
BrainsWay | 134 |
Profound Medical | 131 |
Inozyme Pharma | 59 |
Checkpoint Therapeutics | 23 |
CRBU News
- 3 days ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing - Seeking Alpha
- 3 months ago - Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board - GlobeNewsWire
- 5 months ago - Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential - Seeking Alpha
- 6 months ago - Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 6 months ago - Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire